National Health Act 1953 - Declaration under subsection 85(2AA) (No. PB 13 of 2003)

Overview

The National Health Act 1953, enacted by the Commonwealth Parliament, was established to provide a framework for the administration of health services in Australia, with a strong emphasis on the Pharmaceutical Benefits Scheme (PBS). This legislative instrument, numbered PB 13 of 2003, was introduced to address the need for updating the PBS by removing certain drugs and medicinal preparations from its scope. The policy objective was to ensure that the PBS remains effective and safe for consumers by delisting medications that no longer meet current standards or have been replaced by more effective alternatives. This particular legislative instrument, made under the authority of the Act by Joan Corbett, Assistant Secretary of the Pharmaceutical Benefits Branch and Delegate of the Minister for Health and Ageing, specifies the cessation of the PBS coverage for the drug Thioridazine, effective from 1 November 2003.

Scope and Application

The Pharmaceutical Benefits Declaration under subsection 85(2AA) of the National Health Act 1953 applies to the specific drugs and medicinal preparations listed in the Schedule, which in this instance includes Thioridazine. The Act affects entities and individuals involved in the supply and administration of these pharmaceuticals within the Commonwealth of Australia. It pertains to the Pharmaceutical Benefits Scheme, which is a fundamental component of Australia's health care system, facilitating the provision of affordable medications to the public. The Declaration operates nationally, as it is an instrument of the Commonwealth and applies across all states and territories. The Act does not explicitly state exclusions or exemptions, but its application is limited to the drugs and preparations listed in the Schedule, which, in this case, solely includes Thioridazine. The scope of the Act can be extended or modified through further declarations under the same subsection, subject to the advice of the Pharmaceutical Benefits Advisory Committee and the Minister's delegation.

Key Provisions

The main operative sections of the Declaration under subsection 85(2AA) of the National Health Act 1953 are quite straightforward. Section 1 states that the Declaration commences on 1 November 2003. Section 2 declares that the drugs and medicinal preparations listed in the Schedule to this Declaration will cease to be covered under Part VII of the National Health Act 1953, which pertains to the Pharmaceutical Benefits Scheme. This effectively removes these drugs from the list of those eligible for government subsidies under the Pharmaceutical Benefits Scheme. Under the National Health Act 1953, the obligations imposed on the parties governed by this legislation are primarily administrative and compliance-based. The Assistant Secretary of the Pharmaceutical Benefits Branch, in this case Joan Corbett, must obtain the advice of the Pharmaceutical Benefits Advisory Committee before making such a declaration. This ensures that the decision to remove a drug from the Pharmaceutical Benefits Scheme is informed by expert medical and pharmaceutical advice. Once the advice is obtained, the Assistant Secretary must formally declare the changes in accordance with the requirements of the Act. The Schedule, which lists the drugs affected by this Declaration, must be meticulously prepared to ensure that only the specified drugs are removed from the Scheme. There are no specific offences, penalties, or civil or criminal consequences outlined for breaches of this Declaration. However, any failure to comply with the procedures outlined in the Act, such as not obtaining the necessary advice from the Pharmaceutical Benefits Advisory Committee, could potentially lead to legal challenges or administrative penalties. While the Declaration itself does not specify maximum penalties, breaches of the National Health Act 1953 in general can result in significant legal consequences, including fines and imprisonment, depending on the severity and intent behind the breach. The precise penalties would be determined by the courts based on the specific circumstances of any non-compliance.